Form 4: Regeneron EVP Marion McCourt Executes Stock Option and Sells Shares Under 10b5-1 Plan

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, exercised stock options and sold shares of common stock on June 3, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, executed a transaction involving the company's stock on June 3, 2024.
• McCourt exercised non-qualified stock options to acquire 1,138 shares of common stock at a price of $372.46 per share.
• Simultaneously, McCourt sold 1,138 shares of common stock at a price of $980.16 per share.
• These transactions were executed under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on February 13, 2024.
• Following these transactions, McCourt directly owns 12,931 shares of Regeneron common stock and indirectly owns 174 shares through a 401(k) plan.
• McCourt also holds options for 2,274 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There is no indication of positive or negative sentiment towards the company's prospects.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of insider transactions. Executives often use 10b5-1 plans to sell shares regularly to avoid accusations of trading on inside information. It is common practice among publicly traded companies.

Stakeholder Impact

• The transactions have a minimal impact on stakeholders as they are part of a pre-arranged trading plan and do not indicate a change in the executive's long-term outlook on the company.

Key Dates